Literature DB >> 18165630

Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going?

Christopher M Booth1, Ian Tannock.   

Abstract

Mesh：

Year:  2008        PMID： 18165630     DOI： 10.1200/JCO.2007.13.8156

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

Review 1.  The value of progression-free survival to patients with advanced-stage cancer.

Authors:  Lesley J Fallowfield; Anne Fleissig
Journal:  Nat Rev Clin Oncol       Date:  2011-10-18       Impact factor: 66.675

Review 2.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Klaus Lieb; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2010-04-30       Impact factor: 5.594

3.  Approvals in 2016: questioning the clinical benefit of anticancer therapies.

Authors:  Christopher M Booth; Joseph C Del Paggio
Journal:  Nat Rev Clin Oncol       Date:  2017-02-20       Impact factor: 66.675

Review 4.  Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.

Authors:  Isabel Echavarria; Yolanda Jerez; Miguel Martin; Sara López-Tarruella
Journal:  Breast Care (Basel)       Date:  2017-10-19       Impact factor: 2.860

5.  Approach to the treatment of multiple myeloma: a clash of philosophies.

Authors:  S Vincent Rajkumar; Gösta Gahrton; P Leif Bergsagel
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

Review 6.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Authors:  Lakshmi Nayak; Lisa M DeAngelis; Alba A Brandes; David M Peereboom; Evanthia Galanis; Nancy U Lin; Riccardo Soffietti; David R Macdonald; Marc Chamberlain; James Perry; Kurt Jaeckle; Minesh Mehta; Roger Stupp; Alona Muzikansky; Elena Pentsova; Timothy Cloughesy; Fabio M Iwamoto; Joerg-Christian Tonn; Michael A Vogelbaum; Patrick Y Wen; Martin J van den Bent; David A Reardon
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

7.  Living better or living longer? Perceptions of patients and health care professionals in oncology.

Authors:  Diego de Araujo Toloi; Gabriela Critchi; Andrea Mangabeira; Felipe Matsushita; Rachel P Riechelmann; Paulo M Hoff; Everardo D Saad
Journal:  Ecancermedicalscience       Date:  2015-09-22

8.  Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

Authors:  Huseyin Naci; Courtney Davis; Jelena Savović; Julian P T Higgins; Jonathan A C Sterne; Bishal Gyawali; Xochitl Romo-Sandoval; Nicola Handley; Christopher M Booth
Journal:  BMJ       Date:  2019-09-18

9.  Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer.

Authors:  Nicola Jane Lawrence; Felicia Roncolato; Andrew Martin; Robert John Simes; Martin R Stockler
Journal:  JNCI Cancer Spectr       Date:  2018-11-27

10.  Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Authors:  Yichen Zhang; Huseyin Naci; Anita K Wagner; Ziyue Xu; Yu Yang; Jun Zhu; Jiafu Ji; Luwen Shi; Xiaodong Guan
Journal:  JAMA Netw Open       Date:  2022-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.